Literature DB >> 20077428

Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior.

Dianca R Graham1, Anita Sidhu.   

Abstract

Genetic mutations associated with alpha-synuclein (alpha-Syn) are implicated in the pathogenesis of Parkinson's disease (PD). PD is primarily a movement disorder, but patients are known to experience anxiety and other mood disorders. In this study, we examined the effect of the hA53T mutation during development by analyzing the protein expression of norepinephrine (NET), serotonin (SERT), and dopamine (DAT) transporters in addition to assessing locomotor and anxiety-like behavior. We observed significant decreases in DAT expression at 8 months in transgenic animals compared with normal and younger mice. We used the elevated plus maze, open-field test, and rotarod apparatus to evaluate wild-type and hA53T hemizygous mice at 2, 8, and 12 months of age. Our results showed that 12-month-old transgenic mice spend more time in the open arms and display a greater number of open entries of the elevated plus maze compared with wild-type controls and younger mice. Open-field test results showed that 12-month-old mice travel a greater distance overall and travel more in the inner zone than either wild-type or younger mice. Rotarod testing showed that 8- and 12-month-old transgenic mice perform better than either wild-type controls or younger mice. Overall, 8-12-month-old transgenic mice showed a trend toward reduced anxiety-like behavior and increased hyperactivity. These results indicate a possible role of the A53T alpha-Syn mutation in anxiety-like and hyperactive behaviors in a PD mouse model, suggesting that these behaviors might be comorbid with this disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20077428      PMCID: PMC2861296          DOI: 10.1002/jnr.22331

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  36 in total

1.  Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis.

Authors:  F J Lee; F Liu; Z B Pristupa; H B Niznik
Journal:  FASEB J       Date:  2001-04       Impact factor: 5.191

2.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

Authors:  A Abeliovich; Y Schmitz; I Fariñas; D Choi-Lundberg; W H Ho; P E Castillo; N Shinsky; J M Verdugo; M Armanini; A Ryan; M Hynes; H Phillips; D Sulzer; A Rosenthal
Journal:  Neuron       Date:  2000-01       Impact factor: 17.173

3.  Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation.

Authors:  Y Arai; M Yamazaki; O Mori; H Muramatsu; G Asano; Y Katayama
Journal:  Brain Res       Date:  2001-01-12       Impact factor: 3.252

4.  Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons.

Authors:  D D Murphy; S M Rueter; J Q Trojanowski; V M Lee
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

5.  A role for alpha-synuclein in the regulation of dopamine biosynthesis.

Authors:  Ruth G Perez; Jack C Waymire; Eva Lin; Jen J Liu; Fengli Guo; Michael J Zigmond
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

6.  Regulation of the norepinephrine transporter by alpha-synuclein-mediated interactions with microtubules.

Authors:  Alexis M Jeannotte; Anita Sidhu
Journal:  Eur J Neurosci       Date:  2007-08-20       Impact factor: 3.386

7.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter.

Authors:  B Giros; M Jaber; S R Jones; R M Wightman; M G Caron
Journal:  Nature       Date:  1996-02-15       Impact factor: 49.962

Review 8.  Alpha-synuclein and Parkinson's disease.

Authors:  Alessandra Recchia; Patrizia Debetto; Alessandro Negro; Diego Guidolin; Stephen D Skaper; Pietro Giusti
Journal:  FASEB J       Date:  2004-04       Impact factor: 5.191

9.  Parkinson's disease and anxiety: comorbidity with depression.

Authors:  M A Menza; D E Robertson-Hoffman; A S Bonapace
Journal:  Biol Psychiatry       Date:  1993-10-01       Impact factor: 13.382

10.  Interleukin-1 mediates Alzheimer and Lewy body pathologies.

Authors:  W Sue T Griffin; Ling Liu; Yuekui Li; Robert E Mrak; Steven W Barger
Journal:  J Neuroinflammation       Date:  2006-03-16       Impact factor: 8.322

View more
  42 in total

1.  NACP-Rep1 relates to Beck Depression Inventory scores in healthy humans.

Authors:  Bernd Lenz; Christiane Sysk; Norbert Thuerauf; Marion Clepce; Karin Reich; Helge Frieling; Georg Winterer; Stefan Bleich; Johannes Kornhuber
Journal:  J Mol Neurosci       Date:  2011-01-27       Impact factor: 3.444

Review 2.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

3.  Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours.

Authors:  Bumwhee Lee; Kunwoo Lee; Shree Panda; Rodrigo Gonzales-Rojas; Anthony Chong; Vladislav Bugay; Hyo Min Park; Robert Brenner; Niren Murthy; Hye Young Lee
Journal:  Nat Biomed Eng       Date:  2018-06-25       Impact factor: 25.671

4.  Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD.

Authors:  Silke Nuber; Daniel Tadros; Jerel Fields; Cassia Rose Overk; Benjamin Ettle; Kori Kosberg; Michael Mante; Edward Rockenstein; Margarita Trejo; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-08       Impact factor: 17.088

5.  Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein.

Authors:  Hoa A Lam; Nanping Wu; Ingrid Cely; Rachel L Kelly; Sindalana Hean; Franziska Richter; Iddo Magen; Carlos Cepeda; Larry C Ackerson; Wendy Walwyn; Eliezer Masliah; Marie-Françoise Chesselet; Michael S Levine; Nigel T Maidment
Journal:  J Neurosci Res       Date:  2011-04-12       Impact factor: 4.164

6.  Locomotor differences in mice expressing wild-type human α-synuclein.

Authors:  Genesys Giraldo; Mieu Brooks; Benoit I Giasson; Christopher Janus
Journal:  Neurobiol Aging       Date:  2018-02-06       Impact factor: 4.673

7.  Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.

Authors:  Meghan R Hennis; Marian A Marvin; Charles M Taylor; Matthew S Goldberg
Journal:  Neurobiol Dis       Date:  2013-09-26       Impact factor: 5.996

8.  PET imaging of the influence of physiological and pathological α-synuclein on dopaminergic and serotonergic neurotransmission in mouse models.

Authors:  Elise Levigoureux; Caroline Bouillot; Thierry Baron; Luc Zimmer; Sophie Lancelot
Journal:  CNS Neurosci Ther       Date:  2018-05-20       Impact factor: 5.243

9.  An unexpected improvement in spatial learning and memory ability in alpha-synuclein A53T transgenic mice.

Authors:  Qi Liu; YuYu Xu; WenPing Wan; ZeGang Ma
Journal:  J Neural Transm (Vienna)       Date:  2017-12-07       Impact factor: 3.575

10.  Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.

Authors:  Laura M Butkovich; Madelyn C Houser; Termpanit Chalermpalanupap; Kirsten A Porter-Stransky; Alexa F Iannitelli; Jake S Boles; Grace M Lloyd; Alexandra S Coomes; Lori N Eidson; Maria Elizabeth De Sousa Rodrigues; Danielle L Oliver; Sean D Kelly; Jianjun Chang; Nora Bengoa-Vergniory; Richard Wade-Martins; Benoit I Giasson; Valerie Joers; David Weinshenker; Malú Gámez Tansey
Journal:  J Neurosci       Date:  2020-08-31       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.